Advertisement

RESPONSE TO LETTER TO THE EDITOR - “DOACs versus VKAs were associated with lower odds of all-cause mortality and similar odds of major bleeding”

Published:November 04, 2022DOI:https://doi.org/10.1016/j.ijcard.2022.11.003
      We thank doctor Wang for his questions regarding our study [
      • Wang Y.W.
      DOACs versus VKAs were associated with lower odds of all-cause mortality and similar odds of major bleeding? [published online ahead of print, 2022 Oct 14].
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang Y.W.
        DOACs versus VKAs were associated with lower odds of all-cause mortality and similar odds of major bleeding? [published online ahead of print, 2022 Oct 14].
        Int. J. Cardiol. 2022; (S0167-5273(22)01472-3)https://doi.org/10.1016/j.ijcard.2022.10.004
        • Oliveri F.
        • Montalto C.
        • Tua L.
        • Lanzillo G.
        • Compagnoni S.
        • Fasolino A.
        • Gentile F.R.
        • Ferlini M.
        • Pepe A.
        • Oltrona V.L.
        • et al.
        Direct oral anticoagulants or vitamin K antagonists after TAVR: a systematic review and meta-analysis.
        Int. J. Cardiol. 2022; 365: 123-130https://doi.org/10.1016/j.ijcard.2022.07.039
        • Van Mieghem N.M.
        • Unverdorben M.
        • Hengstenberg C.
        • Möllmann H.
        • Mehran R.
        • López-Otero D.
        • Nombela-Franco L.
        • Moreno R.
        • Nordbeck P.
        • Thiele H.
        • et al.
        Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR.
        N. Engl. J. Med. 2021; 385: 2150-2160https://doi.org/10.1056/NEJMoa2111016